This ATM offering is a clear signal of acute capital needs for a company with $124.7M in accumulated losses and only $8.1M cash. The stock has already lost 62% in two months. With 25.7M additional shares from outstanding warrants and ongoing dilution, expect continued downward pressure. Monitor for further cash burn updates and potential Nasdaq compliance issues given the sub-$0.25 stock price.
Price Chart
Executive Summary
IceCure Medical filed a 424B5 prospectus supplement for an at-the-market (ATM) equity offering of up to $4.34 million in ordinary shares through A.G.P. The offering represents approximately 22% dilution of outstanding shares at the current $0.24 price, with immediate dilution of $0.11 per share (47%) for new investors. This is the company's third equity raise in two months following a $4.0 million March 2026 offering, signaling ongoing cash burn and capital needs for a pre-revenue medical device company.
Key Facts
- ATM offering of up to $4,339,697 in ordinary shares via A.G.P. at 3.0% commission
- 18,082,071 shares would be sold at $0.24/share (May 8 closing price), representing 22% dilution
- Immediate dilution of $0.11 per share (47%) for new investors
- Cash and cash equivalents of $8.1M as of March 31, 2026; pro forma $12.2M after offering
- Accumulated deficit of $124.7M as of March 31, 2026
- Third equity raise in ~7 weeks: $4.0M March 2026 offering + this $4.34M ATM
- 25.7M shares issuable upon exercise of outstanding warrants at $0.55-$1.00 per share
- Stock trading at $0.24, down 62% from $0.629 on March 19, 2026
- Market cap of $19M with $59.3M non-affiliate market value
Financial Impact
Up to $4.34M gross proceeds, net ~$4.1M after 3% commission and ~$110K expenses. Pro forma cash increases from $8.1M to $12.2M. Dilution of 22% of outstanding shares at current price.
Risk Factors
- Substantial dilution from this offering and outstanding warrants/options (total ~29M potential shares)
- Cash burn likely to require additional capital raises within 6-12 months
- Stock price at $0.24 may trigger Nasdaq minimum bid price compliance concerns
- Pre-revenue stage with no disclosed revenue or path to profitability
- Geopolitical risk from Israel-based operations
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 424B5 Filing (Primary) | 0001213900-26-055179 |
| Document: 0001213900-26-055179-index-headers.html | 0001213900-26-055179 |
| Document: 0001213900-26-055179-index.html | 0001213900-26-055179 |
| Document: 0001213900-26-055179.txt | 0001213900-26-055179 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 13, 2026 14d ago | 6-K | $1.10 | awaiting T+60 | — | $1.03 (−6.36%) |
Oct 5, 2026 21d ago | 6-K | $1.27 | awaiting T+60 | — | $1.03 (−18.90%) |
Oct 5, 2026 22d ago | 6-K | $1.54 | awaiting T+60 | — | $1.03 (+33.12%) |
Sep 10, 2026 6w ago | 6-K | $2.14 | awaiting T+60 | — | $1.03 (−51.87%) |
Aug 24, 2026 9w ago | 6-K | $2.27 | awaiting T+60 | — | $1.03 (−54.63%) |
Aug 19, 2026 9w ago | EFFECT | $2.52 | awaiting T+60 | — | $1.03 (+59.13%) |
Aug 14, 2026 10w ago | 6-K | $2.82 | awaiting T+60 | — | $1.03 (−63.48%) |
Aug 12, 2026 10w ago | 6-K | $3.11 | awaiting T+60 | — | $1.03 (−66.83%) |
Jul 6, 2026 16w ago | EFFECT | $4.61 $1.59 | ▲ +65.51% | ▲ +67.23% | $1.03 (+77.66%) |
Jun 26, 2026 17w ago | 6-K | $5.26 $1.95 | ▲ +62.93% | ▲ +67.31% | $1.03 (+80.42%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers